NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
Search
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
collaboration criving innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
Perceived burden of COPD is higher for younger patients
New global survey reveals perceived burden of disease is greater in younger people living with COPD
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Generalized pustular psoriasis: Value of community support
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.